Effectiveness of prestarium in the treatment of chronic cor pulmonale

AIM: To study efficiency and safety of application of perindopril (prestarium) in patients with chronic cor pulmonale (CCP). MATERIAL AND METHODS: The trial included 26 patients with chronic obstructive pulmonary disease complicated with CCP and cardiac failure of NYHA class II-III. The study group of 16 patients received perindopril 2-4 mg/day for 3 months. 10 controls received routine therapy. All the patients were examined before the treatment and 3 months after it using physical examination, echocardiography, Doppler echocardiography, 24-h Holter ECG monitoring, assessment of potassium and creatinine in the serum, quality of life. RESULTS: The treatment decreased functional class of cardiac failure and mean pulmonary arterial pressure, lowered malignant arrhythmia frequency, improved quality of life and intracardiac hemodynamics, inhibited right ventricular remodelling. CONCLUSION: Perindopril is well tolerated and safe efficient medicine in patients with decompensated CCP.